PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Proteins suggest a path to reduce drug resistance in a form of cancer

Proteogenomics provides clues about acute myeloid leukemia

Proteins suggest a path to reduce drug resistance in a form of cancer
2024-02-02
(Press-News.org) RICHLAND, Wash.—Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years. Some patients succumb within just a month or two, despite the battery of drugs used to treat the aggressive blood disease, where blood cells don’t develop properly.

 

A new study draws on a field of science known as proteogenomics to try to improve the outlook. In a paper published Jan. 16 in Cell Reports Medicine, scientists report new findings about how drug resistance in some AML patients develops and how doctors might someday stop or slow the process.

 

The research comes from a team of researchers from the Department of Energy’s Pacific Northwest National Laboratory and Oregon Health & Science University. For nearly a decade, OHSU and PNNL researchers have worked together to fill a critical gap in our knowledge of how cancer and other diseases happen. At one end of the spectrum, our body’s genes can go awry, creating mutations that can be harmful or deadly. At the other end of the spectrum is a real person whose life is affected or even ended as a result.

 

What happens in the middle, between the genes and the person’s health?

 

The answer: a dizzying number of complex molecular processes that scientists are grappling to understand. At the center are the body’s proteins and a field of study known as proteogenomics.

 

Sorting the data with machine learning

The PNNL-OHSU team is studying thousands of proteins that could play a role in AML. Proteins are the body’s molecular workhorses, ferrying nutrients and other supplies back and forth between cells, turning genes on or off, and maintaining dozens of basic body processes. Even though genes get the glory, they do little directly to keep our bodies going. That’s the job of proteins. For nearly 20 years, study author Karin Rodland of OHSU, formerly of PNNL, has been a pioneer exploring the role of proteins in health and disease, building a program with OHSU and PNNL colleagues to study AML.

 

In the latest study, a team led by Sara Gosline, a data scientist and computational biologist at PNNL, did an exhaustive study of the protein activity in 210 patients with AML. Altogether, the team measured levels of nearly half a million pieces of proteins from more than 9,000 proteins in patients’ blood samples. The team combined those findings with extensive data already known about the disease—the genes and mutations involved, the molecular messengers that indicate which genes are active, and the effects of 46 drugs on AML patients, along with information about how the disease progressed in those patients.

 

“We were able to look at patterns of drug responses in hundreds of people by including protein and gene measurements together, and this gave us a level of detail that hasn’t been possible in prior studies,” said Gosline. “This is a great example where we are able to put our growing knowledge of protein signaling and machine learning models to benefit patients in the future.”

 

Gosline and colleagues, including first author James Pino of PNNL, deployed artificial intelligence, using several machine learning algorithms to make sense of the data.

 

Beating drug resistance

While the study yielded a load of data about what happens in the body of an AML patient, one finding stood out, pointing to a possible way to sidestep or delay drug resistance for some patients.

The team showed that treatment with quizartinib, approved last year to treat AML, can shift how cancer cells respond to other drugs often used in combination to treat patients.

 

Specifically, the team found that when patients on quizartinib stop responding to venetoclax, doctors might consider switching to another drug, panobinostat. It’s an example of how proteogenomic information could alter the roadmap that doctors use to navigate which medications patients receive at different stages of the disease.

 

“The difficulty is that cancer keeps evolving,” said Gosline. “You hit the tumor with one drug and the tumor changes. This is what happens when patients experience drug resistance and the medicines stop working. Our study helps us understand exactly how this happens and what might be done in response. Which medication is best to turn to?”


AML poses a particular challenge, said study author Cristina Tognon at OHSU.

 

“When you treat a tumor with a drug, you are putting pressure on the tumor cells as they try to figure out a way to escape that pressure and survive. It’s a big problem in AML patients. What’s even more difficult is that in AML, there are many mutations at work; the disease doesn’t come in just one flavor,” said Tognon, who is an associate research professor and scientific director of the Druker Laboratory at OHSU.

 

Ultimately, the team focused on 147 proteins and specific molecular locations known as phosphosites that play a key role in determining which proteins are turned on and which are off.

 

Using just the protein data, the team sorted the samples into four distinct groups that predicted how the patients fared. Patients whose samples placed them in one of the groups had a better prognosis than the others, surviving far more than five years. Doctors hope that this type of information will eventually become available in the clinic. That would allow some patients who do not need aggressive therapies with severe side effects to avoid them while assuring that patients who have the worst prognosis are treated as aggressively as possible.

 

“There is potential for clinical applications to be derived from this work, for example, diagnostics, such as protein biomarkers to predict responses to therapies, and the design of new drug combinations that might outperform current ones,” said OHSU’s Jeff Tyner, professor of medicine at the OHSU School of Medicine and Knight Cancer Institute.

 

The work is the latest of more than 200 studies that have looked at protein activity in many forms of cancer, including colon, brain, endometrial, brain, blood and ovarian cancers. An OHSU-PNNL team

discussed the emerging role of proteins for treating patients with precision medicine in a recent article in the Annual Reviews of Pharmacology and Toxicology. More and more, scientists are using proteomics—the study of proteins—to bridge the gap between genomics (the study of genes) to phenomics (phenotypes or observable characteristics).

 

 

PMedIC: an OHSU-PNNL collaboration

OHSU and PNNL scientists work collaboratively on many projects. OHSU brings outstanding clinical expertise about disease as well as extensive laboratory knowledge and is a world-class center for new treatments of leukemia. PNNL offers an unparalleled ability to measure tiny amounts of important molecules in great detail. Much of this work happens through the Pacific Northwest Biomedical Innovation Co-Laboratory, or PMedIC, a joint research collaboration between the two organizations. Through PMedIC and other collaborations, the institutions have made discoveries about several diseases, including Alzheimer’s disease, COVID-19, and the Zika virus.

 

At PNNL, additional authors include Camilo Posso, Michael Nestor, Jamie Moon, Joshua Hansen, Chelsea Hutchinson-Bunch, Marina Gritsenko, Karl Weitz, Jason McDermott, Tao Liu and Paul Piehowski. Other authors from OHSU include Sunil Joshi, Kevin Watanabe-Smith, Nicola Long, Brian Druker, Anupriya Agarwal and Elie Traer.

 

This work was supported by the National Cancer Institute’s Office of Cancer Clinical Proteomics Research (CPTAC U01CA271412), the ARCS Scholar Foundation, a Paul & Daisy Soros Fellowship, the National Cancer Institute (F30CA239335, R01 CA229875-01A1), the American Cancer Society (RSG-17-187-01-LIB), the National Heart, Lung, and Blood Institute (R01 HL155426-01), the Alex’s Lemonade Stand Foundation/RUNX1 Research Program, and the EvansMDS Foundation.

 

# # #

END


[Attachments] See images for this press release:
Proteins suggest a path to reduce drug resistance in a form of cancer Proteins suggest a path to reduce drug resistance in a form of cancer 2 Proteins suggest a path to reduce drug resistance in a form of cancer 3

ELSE PRESS RELEASES FROM THIS DATE:

Unveiling Oxidation-induced Super-elasticity in Metallic Glass Nanotubes

Unveiling Oxidation-induced Super-elasticity in Metallic Glass Nanotubes
2024-02-02
Oxidation can degrade the properties and functionality of metals. However, a research team co-led by scientists from City University of Hong Kong (CityU) recently found that severely oxidized metallic glass nanotubes can attain an ultrahigh recoverable elastic strain, outperforming most conventional super-elastic metals. They also discovered the physical mechanisms underpinning this super-elasticity. Their discovery implies that oxidation in low-dimension metallic glass can result in unique properties for ...

Ambitious workers park the office politics when employer is struggling, study suggests

2024-02-02
One of the study authors, Professor Hans Frankort, Professor of Strategy at Bayes Business School, City, University of London, said: “Sports – particularly motorsports – can be a good proxy for several other industries as they are extremely competitive: if you don’t perform and progress you may be out. Workers in sectors such as consultancy and financial services face similar pressures.” The peer reviewed paper, which has been published on the website of the Academy of Management Journal, found that riders systematically adjusted their internal ...

Speech Accessibility Project begins recruiting people who have had a stroke

2024-02-02
The Speech Accessibility Project has begun recruiting U.S. and Puerto Rican adults who have had a stroke. Those interested can sign up online. Funded by Big Tech companies Amazon, Apple, Google, Meta, and Microsoft, the University of Illinois Urbana-Champaign aims to train voice recognition technologies to understand people with diverse speech patterns and disabilities. The project is also recruiting adults with Parkinson’s disease, Down syndrome, cerebral palsy, and amyotrophic lateral sclerosis. “A stroke can cause big changes, including changes to your ability to speak,” said Mark Hasegawa-Johnson, the project’s ...

Urgent need to address health equity at intersection of American Heart Month and Black History Month 2024

2024-02-02
DALLAS, Feb. 2, 2024 — Black Americans have the highest incidence of cardiac arrest outside of the hospital and are significantly less likely to survive.[1] Cardiac arrest in Black neighborhoods is associated with alarmingly low treatment and survival rates and recent studies have shown lower rates of both bystander CPR and bystander AED use in these neighborhoods. Recognizing the unique intersection of American Heart Month and Black History Month, the American Heart Association, celebrating 100 years of service saving lives, marks the occasion by honoring ...

NRG Oncology selects Health Equity Fellows for 2024

2024-02-02
PHILADELPHIA, PA – NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group, recently announced that they have named two health equity fellows as a part of the organization’s Health Equity Fellowship Program. Fellowship awardees include Dr. Onyinye Balogun and Dr. Stephanie Rieder. NRG’s Health Equity Fellowship Program was established by Joan Walker, MD, of the University of Oklahoma and an NRG NCI Community Oncology Research Program (NCORP) Principal Investigator, to train selected ...

Neptune-like exoplanets can be cloudy or clear — new findings suggest the reason why

Neptune-like exoplanets can be cloudy or clear — new findings suggest the reason why
2024-02-02
LAWRENCE — The study of “exoplanets,” the sci-fi-sounding name for all planets in the cosmos beyond our own solar system, is a pretty new field. Mainly, exoplanet researchers like those in the ExoLab at the University of Kansas use data from space-borne telescopes such as the Hubble Space Telescope and Webb Space Telescope. Whenever news headlines offer findings of “Earth-like” planets or planets with the potential to support humanity, they’re talking about exoplanets within our own Milky Way. Jonathan Brande, a doctoral candidate in the ExoLab at the University of Kansas, has just published findings in the open-access ...

nTIDE January 2024 Jobs Report: Despite minor shifts, employment for people with disabilities remains near historic highs

nTIDE January 2024 Jobs Report: Despite minor shifts, employment for people with disabilities remains near historic highs
2024-02-02
East Hanover, NJ – February 2, 2024 – Labor market indicators showed slight declines over the last two months for both people with and without disabilities, according to today’s National Trends in Disability Employment – semi-monthly update (nTIDE), issued by Kessler Foundation and the University of New Hampshire’s Institute on Disability (UNH-IOD). These declines may reflect the end of seasonal employment and the impact of the Federal Reserve’s anti-inflationary measures aimed at minimizing the risk of recession. ...

NRL joins Airborne and Satellite Investigation of Asian Air Quality (ASIA-AQ)

NRL joins Airborne and Satellite Investigation of Asian Air Quality (ASIA-AQ)
2024-02-02
WASHINGTON  –  U.S. Naval Research Laboratory (NRL) meteorologists, in partnership with NASA, will join a team of international scientists to participate in the Airborne and Satellite Investigation of Asian Air Quality (ASIA-AQ) experiment beginning on February 2.   NRL’s collaborators, David Peterson, Ph.D., meteorologist, Theodore McHardy, Ph.D., American Society for Engineering Education postdoctoral researcher, Nicholas Gapp, Science Applications International Corporation ...

New drug could prevent diabetic eye and kidney disease in people with diabetes

2024-02-02
New research has shown a new type of inhibitor drug could prevent microvascular diabetic complications, such as diabetic eye and kidney disease.  The University of Bristol-led research is published in Cardiovascular Diabetology. Diabetes, a disease which results in uncontrolled blood glucose levels, is estimated to affect one in 11 adults worldwide.  Even when managed, this common disease can result in life-altering complications, impacting the small blood vessels of the body, known as the microvasculature.   While treatments ...

UT research breaking records, growing impact in Tennessee and beyond

UT research breaking records, growing impact in Tennessee and beyond
2024-02-02
The University of Tennessee, Knoxville, continued to expand its impact and research footprint last year, breaking university records for both research expenditures and sponsored project awards for the second straight year. Since 2019, UT has more than doubled its sponsored project awards, reaching a record $428 million in the fiscal year that ended in June 2023. The university also reported $339 million in research expenditures in fiscal year 2023, an increase of nearly $15 million over fiscal year 2022 and the highest amount in UT history. Research expenditures include internal and external funds that support UT research ...

LAST 30 PRESS RELEASES:

Resistance training may improve nerve health, slow aging process, study shows

Common and inexpensive medicine halves the risk of recurrence in patients with colorectal cancer

SwRI-built instruments to monitor, provide advanced warning of space weather events

Breakthrough advances sodium-based battery design

New targeted radiation therapy shows near-complete response in rare sarcoma patients

Does physical frailty contribute to dementia?

Soccer headers and brain health: Study finds changes within folds of the brain

Decoding plants’ language of light

UNC Greensboro study finds ticks carrying Lyme disease moving into western NC

New implant restores blood pressure balance after spinal cord injury

New York City's medical specialist advantage may be an illusion, new NYU Tandon research shows

Could a local anesthetic that doesn’t impair motor function be within reach?

1 in 8 Italian cetacean strandings show evidence of fishery interactions, with bottlenose and striped dolphins most commonly affected, according to analysis across four decades of data and more than 5

In the wild, chimpanzees likely ingest the equivalent of several alcoholic drinks every day

Warming of 2°C intensifies Arctic carbon sink but weakens Alpine sink, study finds

Bronze and Iron Age cultures in the Middle East were committed to wine production

Indian adolescents are mostly starting their periods at an earlier age than 25 years ago

Temporary medical centers in Gaza known as "Medical Points" (MPs) treat an average of 117 people daily with only about 7 staff per MP

Rates of alcohol-induced deaths among the general population nearly doubled from 1999 to 2024

PLOS One study: In adolescent lab animals exposed to cocaine, High-Intensity Interval Training boosts aversion to the drug

Scientists identify four ways our bodies respond to COVID-19 vaccines

Stronger together: A new fusion protein boosts cancer immunotherapy

Hidden brain waves as triggers for post-seizure wandering

Music training can help the brain focus

Researcher develop the first hydride ion prototype battery

MIT researchers find a more precise way to edit the genome

‘Teen’ pachycephalosaur butts into fossil record

Study finds cocoa extract supplement reduced key marker of inflammation and aging

Obesity treatment with bariatric surgery vs GLP-1 receptor agonists

Nicotinamide for skin cancer chemoprevention

[Press-News.org] Proteins suggest a path to reduce drug resistance in a form of cancer
Proteogenomics provides clues about acute myeloid leukemia